Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia.
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
To evaluate the effects of the sodium glucose cotransporter 2 (SGLT2) inhibitor empagliflozin
added to metformin for 12 weeks in patients with type 2 diabetes.